Abrol - mucolytic with a pronounced expectorant effect.
Treatment of acute and chronic bronchopulmonary diseases, accompanied by a violation of bronchial secretion and a deterioration in the movement of mucus.
Mode of application
The drug is taken orally after or during a meal..
Pills.
Children over 12 years of age and adults: 1 tablet three times a day. In order to achieve a faster therapeutic effect, you can take 2 tablets twice a day, taking pills with water after meals.
Children 6 up to 12 years old: 1⁄2 tablets 2-3 р / д.
The course of treatment - up to 4-5 days. Longer therapy must be approved by a physician.
Syrup in the form of 5/5ml.
Used in pediatric practice. Dosage for children according to age:
The course of treatment - up to 4-5 Nights. Above - only after consulting a doctor.
Syrup in the form of 30/5ml.
Dosage for children according to age:
Adults and children over 12 years old: 5 ml 3 times during the first 2-3 days, hereinafter 5 ml 2 р / д.
There are currently no reported cases of overdose. Symptoms, known from rare overdose reports and / or misuse of medication, meet the known side effects of ambroxol hydrochloride at recommended doses and require symptomatic treatment.
On the part of the immune system, Skin and subcutaneous tissue: itch, эritema, rash, hives, angioedema, anaphylactic reactions (including anaphylactic shock), other hypersensitivity reactions, severe skin lesions (Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), Acute generalized exanthematous pustulosis).
From the nervous system: disgevziya (changes in taste sensations).
From the gastrointestinal tract: diarrhea, nausea, vomiting, dyspepsia, abdominal pain, dry mouth, heartburn, constipation, drooling, dry throat.
The respiratory system, chest and mediastinal organs: decreased sensation in the throat, breathlessness (including as a symptom of a hypersensitivity reaction), bronchospasm, rhinorrhea, dry airways.
From the urinary system: dizurija.
General disorders: mucosal reactions, fever.
The drug is contraindicated in case of established individual sensitivity to the active substance and / or other components of the drug.
The drug in the form of tablets is contraindicated in children under 6 years of age..
Abrol is prohibited for use in 1 trimester of pregnancy and during breastfeeding. It should also be used with caution after 28 week of pregnancy.
As a result of taking ambroxol and antibacterial agents (Erythromycin, amoksiцillin, cefuroxime) their concentration in bronchial secretions increases.
It is undesirable to use antitussives in conjunction with ambroxol, tk. in this case, the mucus stagnates in the pulmonary tree.
Abrol removes accumulated mucus, which effectively helps to eliminate it and thus reduces coughing.
Ambroxol hydrochloride, as the active substance of the drug Abrol, has multiple activities:
Ambroxol hydrochloride also has local anesthetic and mild antitussive effect. Affects the production of arachidonic acid in the body, eliminating free radical oxidation in the focus of inflammation. The drug enhances the action of antibacterial drugs.
After oral administration of Abrol, drug substances are absorbed at a high rate. Cmax is determined in blood plasma after 1-1,5 o'clock. Substances of the drug are closely related to albumin (to 90%). Decomposition of the drug occurs in the liver, as a result of its conversion to glucose, a metabolite is formed - dibromanthranilic acid.
The half-life is 10-12 hours. To 6% the drug is in free form,26% settles in the form of conjugates in the urinary system. With chronic renal failure, the concentration of ambroxol increases, which causes an increase in its concentration in blood plasma more than in 3 times. The drug is excreted in the urine and partly in the feces.
In patients with impaired liver function, the excretion of ambroxol hydrochloride is reduced, which leads to 1,3-2 times higher than the plasma level. Since the therapeutic range of ambroxol hydrochloride is quite wide, no need to change dosage.
Age and gender do not have a clinically significant effect on the pharmacokinetics of ambroxol hydrochloride., therefore no dose adjustment is required..
Food intake does not affect the bioavailability of ambroxol hydrochloride..
Ambroxol hydrochloride is a substituted benzylamine and a metabolite of bromhexine. Proved, that ambroxol hydrochloride increases airway glandular secretion and enhances pulmonary surfactant secretion by direct action on type II pneumocytes in the alveoli and Clara cells in the bronchioles. Ambroxol hydrochloride also stimulates ciliary activity., which facilitates the secretion of mucus and its removal (mucociliary clearance). Activation of fluid secretion and increased mucociliary clearance facilitate mucus clearance and relieve coughing.
Ambroxol hydrochloride has a local anesthetic effect due to reversible and concentration-dependent blocking of neuronal sodium channels.. There are also data, that ambroxol hydrochloride has anti-inflammatory (due to a significant decrease in the release of cytokines from the blood and tissue binding of mononuclear and polymorphonuclear cells).
In patients with pharyngitis, the use of ambroxol hydrochloride resulted in a significant reduction in pain and redness in the throat..
The use of ambroxol hydrochloride increases the concentration of antibiotics (amoksiцillina, tsefuroksyma, erythromycin and doxycycline) in bronchopulmonary secretions and sputum.
Active material: in 5 ml of syrup contains ambroxol hydrochloride 15 (30) mg.
Excipients:
1 the tablet contains ambroxol hydrochloride 30 mg. Excipients: Colloidal anhydrous silica, sodium croscarmellose, microcrystalline cellulose,magnesium stearate.
Product form
Storage conditions
Store at a temperature not exceeding 25 degrees. After opening the vial, the drug retains its properties no more than 28 days. Keep in a safe place out of reach of children. Shelf life 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More